Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Filgrastim-sndz"'
Autor:
Daniel J. Weisdorf, Molly M. Jeffery, Jessica Chang, Pinar Karaca-Mandic, Stephen W. Schondelmeyer, Ronald S. Go
Publikováno v:
Health affairs (Project Hope). 38(11)
In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b935261164c2162d2e883af35e42396
https://pubmed.ncbi.nlm.nih.gov/31682491
https://pubmed.ncbi.nlm.nih.gov/31682491
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Clinical Oncology. 38:73-73
73 Background: According to clinical practice guidelines, the threshold for routine myeloid growth factor (MGF) PP is a high risk (>20%) of developing FN. However, in response to the COVID-19 pandemic, a recent recommendation expands this threshold f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c3f702175abdfe41e23f546ba437ad
https://doi.org/10.1200/jco.2020.38.29_suppl.73
https://doi.org/10.1200/jco.2020.38.29_suppl.73
Publikováno v:
Journal of Clinical Oncology. 38:e19401-e19401
e19401 Background: Patients with nonmetastatic NSCLC receiving platinum-based chemotherapy are at an intermediate risk (10-20%) of developing FN; clinical practice guidelines recommend assessing whether these patients have FN risk factors before cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c158702eef07fe8aec58b61bf3cc3986
https://doi.org/10.1200/jco.2020.38.15_suppl.e19401
https://doi.org/10.1200/jco.2020.38.15_suppl.e19401
Publikováno v:
Journal of medical economics. 21(6)
McBride et al.1 recently published what was referred to as “cost-efficiency analyses”. The analyses completed by the authors compared four alternative granulocyte colony-stimulating factor (G-CSF) ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a540bbf28b73f60e9fbc5a9de0d52bb
https://pubmed.ncbi.nlm.nih.gov/28722494
https://pubmed.ncbi.nlm.nih.gov/28722494
Publikováno v:
Expert Opinion on Biological Therapy. 16:137-142
On March 6(th) 2015, the Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio) as the first biosimilar in the United States (US) for all indications of the reference product. Filgrastim-sndz is a biosimilar of Amgen's Neupogen and is m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eef35f2337e5c0ddde1c4150bd68d9e
https://doi.org/10.1517/14712598.2016.1128410
https://doi.org/10.1517/14712598.2016.1128410
Publikováno v:
Journal of medical economics. 20(10)
Aims: Guidelines recommend prophylaxis with granulocyte colony-stimulating factor for chemotherapy-induced (febrile) neutropenia (CIN/FN) based on regimen myelotoxicity and patient-related risk factors. The aim was to conduct a cost-efficiency analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda49917fa7804f36ed52bc676ccdadd
https://pubmed.ncbi.nlm.nih.gov/29561198
https://pubmed.ncbi.nlm.nih.gov/29561198
Engraftment with Filgrastim-Sndz Versus Filgrastim in Adult Autologous Stem Cell Transplant Patients
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S333-S334
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5097e72856c956882f8291546929c4d8
https://doi.org/10.1016/j.bbmt.2017.12.279
https://doi.org/10.1016/j.bbmt.2017.12.279
Autor:
Jane De Lartigue
Publikováno v:
The Journal of Community and Supportive Oncology. 13:420-422
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93c3cc97a2299cf07df2b0a3129c506d
https://doi.org/10.12788/jcso.0203
https://doi.org/10.12788/jcso.0203
Publikováno v:
Journal of Clinical Oncology. 36:140-140
140 Background: G-CSFs are utilized to lower the incidence of febrile neutropenia (FN) in patients with cancers treated with chemotherapy. In 2015 filgrastim-sndz was the first biosimilar to be approved and launched in the US. Limited data exists on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::623b5e59a4228347f80926df7d1f646d
https://doi.org/10.1200/jco.2018.36.34_suppl.140
https://doi.org/10.1200/jco.2018.36.34_suppl.140